Genomate Health Welcomes Digosys (Thabis) as Vietnam Exclusive Distributor

November 04, 2024 11:00 PM AEDT | By EIN Presswire
 Genomate Health Welcomes Digosys (Thabis) as Vietnam Exclusive Distributor
Image source: EIN Presswire
CAMBRIDGE, MA, UNITED STATES, November 4, 2024 /EINPresswire.com/ -- Genomate Health Inc., a global leader in computational intelligence-driven precision oncology, is proud to announce a strategic partnership with Thabis, one of Vietnam’s healthcare innovators, and its subsidiary Digosys, to bring cutting-edge cancer treatment solutions to the country. This collaboration aims to provide oncologists and patients with access to personalized, data-driven therapies, ushering in a new era of cancer care in Southeast Asia.

Thabis, a pioneering healthcare provider in Vietnam, has an extensive track record of advancing medical care through innovation. Its subsidiary, Digosys, is committed to transforming cancer care throughout the region. Through this exclusive partnership, Digosys will leverage its extensive healthcare network and local expertise to distribute Genomate Health's flagship product, Genomate®, across Vietnam through its Genous™ service. Genous™, built on the cutting-edge technology of Genomate®, is a comprehensive service designed to combine next-generation sequencing, Genomate's proprietary computational engine, and human-powered Molecular Tumor Board interpretation to deliver optimal treatment recommendations for each patient.

This collaboration was introduced to the Vietnamese healthcare community at the AI4VN 2024 conference in Hanoi. Deputy Prime Minister Tran Luu Quang, who visited the Genous™ booth, expressed strong interest in the innovative cancer treatment solution, signaling the Vietnamese government’s support for healthcare advancements and technology-driven solutions in oncology. This high-level engagement reflects the country’s growing emphasis on healthcare innovation and the role of public-private partnerships in improving patient outcomes.

In November 2024, Genous™ will further solidify its presence in Vietnam through a series of in-person events led by Genomate Health’s Founder and CEO, Dr. Istvan Petak. Hosted by prestigious medical institutions such as Hanoi Oncology Hospital and K Hospital, these events will showcase Genomate Health’s advanced cancer treatment solutions to Vietnam’s top oncologists and healthcare leaders. The presentations will focus on the latest breakthroughs in precision oncology, including AI-driven molecular profiling, targeted therapy, and immunotherapy optimization, providing a platform for knowledge exchange and fostering collaborations with local experts​.

“We are honored to partner with Genomate Health, a global innovator in precision oncology,” said Luong Huu Hanh, Chairman of Thabis. “At Thabis and Digosys, our mission is to bring world-class healthcare solutions to Vietnam, and this collaboration will help us deliver on that promise. Deputy Prime Minister Tran Luu Quang’s interest at the AI4VN 2024 conference reaffirmed the importance of this work, and we are excited to introduce these life-changing technologies to oncologists across Vietnam.”

Their combined efforts will ensure widespread awareness and adoption of precision oncology in Vietnam. Dr. Istvan Petak, MD, PhD, CEO and Founder of Genomate Health, underscored the partnership’s potential: "Vietnam is rapidly emerging as a hub for healthcare innovation, and our collaboration with Thabis and Digosys marks a significant step in making personalized oncology care more accessible. Genomate’s computational intelligence-powered solutions, combined with Digosys’s local expertise and network, will enable oncologists to deliver patients data-driven, customized cancer treatments.".

The partnership comes at a crucial time as cancer rates in Vietnam continue to rise, with over 165,000 new cancer cases reported annually (WHO report). With the help of Genous™, Vietnamese patients and oncologists will gain access to personalized treatment recommendations backed by international research, potentially improving survival rates and reducing treatment costs. Genomate Health and Digosys aim to make their technology available to healthcare providers nationwide and to reach thousands of cancer patients annually.

About Genomate Health
Genomate Health Inc. is a medical technology company based in Cambridge, MA, developing computational solutions for personalized medicine. Its flagship product, Genomate®, is the first clinically validated universal computational reasoning model to predict response to multiple targeted therapies by analyzing each patient's unique combinations of genetic alterations and biomarkers. Genomate® delivers the first computational reasoning solution to implement the true promise of precision oncology of N-of-1 therapy based on the genomic profile of the patient’s tumor. For more information, visit www.genomate.health.

About Thabis/Digosys
Thabis is a prominent healthcare provider in Vietnam known for its dedication to driving healthcare innovation across the region. Its subsidiary, Digosys, specializes in digital health solutions, focusing on improving cancer care by integrating advanced technologies. For more information, please visit www.digosys.com.

Alina Luchian, Marketing & Brand Manager
Genomate Health
[email protected]
Visit us on social media:
LinkedIn
YouTube
Facebook
Instagram

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.